<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Peter Friebe on Medium]]></title>
        <description><![CDATA[Stories by Peter Friebe on Medium]]></description>
        <link>https://medium.com/@scienceworthknowing?source=rss-9dd71b53ebca------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*ryDgNSNqBXPVfmuKia_92A.png</url>
            <title>Stories by Peter Friebe on Medium</title>
            <link>https://medium.com/@scienceworthknowing?source=rss-9dd71b53ebca------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 03:06:50 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@scienceworthknowing/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Mosquito-Borne Diseases: Zika, Yellow Fever, Chikungunya, and Japanese Encephalitis]]></title>
            <link>https://scienceworthknowing.medium.com/mosquito-borne-diseases-zika-yellow-fever-chikungunya-and-japanese-encephalitis-8bf65825b4d2?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/8bf65825b4d2</guid>
            <category><![CDATA[mosquito-borne-diseases]]></category>
            <category><![CDATA[chikungunya]]></category>
            <category><![CDATA[zika-virus]]></category>
            <category><![CDATA[yellow-fever]]></category>
            <category><![CDATA[japanese-encephalitis]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Mon, 16 Nov 2026 23:52:10 GMT</pubDate>
            <atom:updated>2026-11-16T23:52:10.765Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-aKw_CCSDYRQ5VegEQ50Og.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p><strong>Mosquito-Borne Diseases: Zika, Yellow Fever, Chikungunya, and Japanese Encephalitis</strong></p><p>In my article about <a href="https://scienceworthknowing.medium.com/can-we-eliminate-malaria-d8f37eb0663c"><strong>malaria</strong></a>, I mention that mosquitoes are the deadliest animals for humans. Malaria is caused by a parasite, but mosquitoes can also transmit viruses, which I have partially covered in my articles about <a href="https://medium.com/@scienceworthknowing/dengue-a-growing-global-health-threat-604ac2cbfcb8"><strong>dengue</strong></a> and <a href="https://medium.com/@scienceworthknowing/west-nile-virus-bc34cb270aff"><strong>West Nile</strong></a>. But these are not the only viruses, and there are many more, so let’s focus on a few of the other mosquito-borne viruses: Zika, yellow fever, chikungunya, and Japanese encephalitis.</p><p>Before looking at each virus and its associated disease more closely, it is worth mentioning that all these viruses have single-stranded, positive-sense RNA genomes. This means their RNA can be used directly to produce viral proteins once the virus has infected a target cell. Dengue, West Nile, Zika, yellow fever, and Japanese encephalitis belong to the same virus family (Flaviviridae) and are therefore closely related, whereas chikungunya virus belongs to another family (Togaviridae).</p><p>OK, let’s take a look at each virus and its associated disease. As always, this article is simplified and intended to provide an overview of each disease.</p><p><strong>Zika (ZIKV): A Particular Danger During Pregnancy</strong></p><p>Zika virus has been around for a long time but was regarded as a relatively harmless mosquito-borne virus. It was first discovered in Uganda in 1947 in a monkey and identified in humans in the 1950s. The virus seemed to cause no symptoms or only mild symptoms, such as fever, rash, joint pain, and conjunctivitis (red eyes), and patients generally recovered quickly on their own.</p><p>But Zika virus can be much more dangerous, which we learned during a large outbreak in the Americas in 2015 and 2016, particularly in Brazil. In pregnant women, the virus can infect the developing fetus, and this can lead to serious developmental abnormalities. The complications, known as congenital Zika syndrome, include microcephaly (the baby’s brain and head do not develop normally), vision and hearing problems, and pregnancy loss.</p><p>In rare cases, Zika can cause Guillain-Barré syndrome, in which the immune system attacks the nerves and causes muscle weakness or paralysis. It is also important to know that Zika can be sexually transmitted.</p><p>Reported infections have declined substantially since the 2015–2016 epidemic, but Zika has not disappeared. The main mosquito transmitting Zika is <em>Aedes aegypti</em>, which can also transmit dengue, chikungunya, and yellow fever. There is currently no approved vaccine or specific antiviral treatment.</p><p><strong>Yellow Fever: A Deadly Disease With an Effective Vaccine</strong></p><p>Yellow fever gets its name from jaundice, the yellowing of the skin and eyes caused by liver damage. Historical descriptions consistent with yellow fever date back to the 1600s.</p><p>Yellow fever occurs primarily in tropical regions of Africa and Central and South America, where the virus circulates between mosquitoes and nonhuman primates. But the virus can infect humans as well, and the main mosquito involved in urban transmission is <em>Aedes aegypti, </em>the same species responsible for much of the transmission of dengue and Zika.</p><p>Most infected people either don’t develop clinical symptoms or experience a few days of fever, headache, and muscle pain before they fully recover. But in some patients, the virus can be more dangerous and lead to severe liver and kidney damage, bleeding, and organ failure. This more severe phase of the infection often occurs after patients initially start to recover from their symptoms, and the risk of death is high for patients who develop this severe phase.</p><p>While there is no specific antiviral treatment for patients infected with the virus (treatment is supportive), there is a very effective vaccine, which was developed in the 1930s. The vaccine uses a live-attenuated virus, which can sound scary, but it is very effective and generally provides lifelong protection after a single dose. Although live-attenuated vaccines are generally safe for healthy individuals, the yellow fever vaccine can very rarely cause severe side effects. If you want to learn more about live-attenuated vaccines and how they work, please read my article “<a href="https://medium.com/@scienceworthknowing/lets-talk-about-vaccines-07252c21cece"><strong>Let’s Talk About Vaccines</strong></a>”.</p><p>I mentioned above that the natural yellow fever transmission cycle is between mosquitoes and nonhuman primates. Interestingly, African monkeys generally develop mild or no symptoms. They serve as hosts: the virus can multiply in them and infect mosquitoes, but the monkeys rarely develop severe disease. This is different for some monkey species in South America, which can become severely ill and even die if infected with yellow fever. Outbreaks in monkeys can therefore serve as early warning signals for yellow fever transmission in an area.</p><p><strong>Japanese Encephalitis: A Virus That Can Attack the Brain</strong></p><p>Japanese encephalitis virus is found across much of Asia and parts of the western Pacific, including Australia. The virus is closely related to West Nile virus and, like West Nile, is transmitted mainly by <em>Culex</em> mosquitoes. The virus circulates primarily between mosquitoes, pigs, and certain birds. Humans can also become infected through mosquito bites, but they generally do not develop enough virus in their blood to infect mosquitoes.</p><p>As with West Nile, most infections cause no symptoms, but in rare cases a severe illness involving the central nervous system can develop. In these cases, patients can develop encephalitis, an inflammation of the brain, leading to confusion, seizures, paralysis, and potentially coma. Among those who develop encephalitis, approximately 20–30% die, and many survivors experience lasting neurological problems.</p><p>Just like yellow fever, there is no specific antiviral treatment, but there are several highly effective vaccines available, including inactivated, live-attenuated, and recombinant vaccines. The recombinant vaccine uses a modified yellow fever vaccine virus that carries the genes encoding Japanese encephalitis virus surface proteins. All these vaccines are highly effective and generally very safe.</p><p><strong>Chikungunya: When Joint Pain Lasts for Months</strong></p><p>The last viral disease for this article is chikungunya, which is transmitted primarily by <em>Aedes</em> mosquitoes. It occurs in parts of Africa, Asia, and the Americas, but outbreaks have also been reported in other regions, such as Europe.</p><p>Most people infected with chikungunya develop symptoms, which can include high fever, headache, muscle pain, joint swelling, rash and severe joint pain. Most people recover from the acute infection within a week or two, but the joint pain can persist for months or even years, substantially affecting their quality of life.</p><p>The good news is that we now have chikungunya vaccines available. In the United States, the first vaccine was approved in 2023, but the FDA suspended its license in 2025 due to reports of serious adverse events. A second vaccine was approved in early 2025 and remains available in the United States. Both vaccines have received approvals in several other countries, although availability and recommendations differ between countries.</p><p><strong>In Summary</strong></p><p>Mosquitoes are the deadliest animals for humans, transmitting a variety of pathogens, including parasites and viruses.</p><p>While the viruses discussed in the article do not always cause clinical symptoms (an infection without symptoms is called asymptomatic), each of the viruses can cause devastating outcomes. Zika is associated with complications during pregnancy. Yellow fever can cause fatal liver disease. Chikungunya can leave patients with prolonged, sometimes disabling joint pain, and Japanese encephalitis can cause severe neurological damage.</p><p>As there is no specific antiviral treatment for any of these diseases, prevention is most important, be it protection against mosquito bites, or vaccination when available.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8bf65825b4d2" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can We Eliminate Malaria?]]></title>
            <link>https://scienceworthknowing.medium.com/can-we-eliminate-malaria-d8f37eb0663c?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/d8f37eb0663c</guid>
            <category><![CDATA[malaria]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Thu, 12 Nov 2026 22:53:06 GMT</pubDate>
            <atom:updated>2026-11-12T22:53:06.052Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TZGBrb7DPUJWOiTpmeGwTw.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>Mosquitoes are the deadliest animals for humans, responsible for an estimated 700,000 deaths worldwide each year. The deaths are not caused by the mosquitoes themselves, but by diseases transmitted when mosquitoes take a blood meal. More than 80% of these deaths are attributed to malaria, a disease caused by single-celled parasites belonging to a group called <em>Plasmodium</em>. In 2024, an estimated 282 million new malaria cases occurred worldwide. The majority of infections and deaths happen in Africa, with young children bearing the greatest burden.</p><p>These are shocking numbers, and, at first glance, seem to give a clear “no” as an answer to the question “Can we eliminate malaria?” But the World Health Organization (WHO) aims for a 90% reduction in malaria incidence and mortality rates by 2030 (relative to 2015), and the Pan American Health Organization (PAHO) aims for a reduction in malaria incidence of 50% across the Americas by 2030 (relative to 2024).</p><p>To better understand if these aims are feasible, let’s first discuss the disease, and then the tools available to fight malaria.</p><p><strong>How Does <em>Plasmodium</em> Spread?</strong></p><p>While most infectious diseases transmitted by mosquitoes are caused by viruses (such as dengue, Zika, West Nile and many more), malaria is caused by the parasite <em>Plasmodium</em>. There are several species of <em>Plasmodium</em> that infect humans, but <em>P. falciparum</em> is the deadliest and is responsible for most infections in Africa. Outside of Africa, <em>P. vivax</em> is widespread.</p><p>The parasite is transmitted primarily through infected female <em>Anopheles</em> mosquitoes. These mosquitoes are generally most active between dusk and dawn, making mosquito nets an effective defense. But if an infected mosquito takes a blood meal, the parasites (at this stage called sporozoites) are introduced into the bloodstream and travel to the liver, where they infect liver cells and start to multiply. One parasite can produce thousands of daughter parasites (called merozoites) in a liver cell. This can take several days, depending on the species. At the end, the merozoites leave the liver and are released into the bloodstream.</p><p>The merozoites then invade red blood cells. <em>Plasmodium</em> now multiplies inside the infected red blood cell and produces approximately 16–32 daughter parasites (for <em>P. falciparum</em>) before the red blood cell ruptures and the new parasites are released to infect more red blood cells. The rupture of infected red blood cells releases parasites and triggers inflammation, causing some of malaria’s symptoms, such as fever and chills. The infection cycle (multiplication and rupture of red blood cells) can also become synchronized, resulting in recurring fever every two or three days.</p><p>Over time, the repeated cycle can deplete the body of red blood cells, reducing oxygen delivery and leading to fatigue and weakness. <em>P. falciparum</em> can also cause severe organ damage because infected red blood cells can adhere to small blood vessels, thereby impairing circulation and triggering inflammation.</p><p>So far, I have described how the parasite multiplies by making identical copies of itself. But the <em>Plasmodium</em> life cycle is far more complicated, and it also produces male and female gametocytes, which mosquitoes can ingest during a blood meal and which can develop further inside them. I won’t go into details, but sexual reproduction and further multiplication inside the mosquito produce new sporozoites, which can then infect humans whenever the mosquito has a blood meal.</p><p>I also need to mention that <em>P. vivax</em> (and <em>P. ovale</em>) can leave dormant forms in the liver. These forms do not immediately multiply and release daughter parasites to infect red blood cells. Instead, they remain inactive and hidden in the liver for months or even years. These dormant forms can later reactivate, meaning they start to multiply in liver cells, and the daughter parasites then infect red blood cells. This can cause malaria in patients who had malaria before and appeared to be cured.</p><p><strong>What Are the Signs of Malaria?</strong></p><p>I mentioned some of the signs in the previous section. Early symptoms can include fever, chills, headache, muscle aches, fatigue, and sometimes nausea or vomiting. In other words, the symptoms resemble the flu.</p><p>But malaria can become life-threatening, particularly when caused by <em>P. falciparum</em>. The loss of red blood cells can cause severe anemia. Infected red blood cells can also accumulate in small blood vessels, interfering with blood flow and damaging vital organs. This can affect the brain and cause cerebral malaria, which can lead to seizures, coma, and potentially death.</p><p>The severity of malaria can depend on many factors. People who have had infections before often develop partial immunity, which reduces the risk of severe illness, but does not necessarily prevent infection.</p><p>This also means that people who have never had malaria are more vulnerable to severe forms of the disease. Travelers from malaria-free countries and young children are in this category. Additionally, malaria can interfere with pregnancy and fetal development.</p><p>Another factor influencing malaria severity lies in our genes. People who carry one copy of the sickle cell variant have some protection against severe malaria. However, people who inherit two copies develop sickle cell disease, which can be serious. In fact, the protection against severe malaria provided by carrying one copy helped this genetic variant persist in human populations, despite the harmful consequences of inheriting two.</p><p><strong>Treatment and Vaccines</strong></p><p>Prevention remains an important control mechanism. This includes using mosquito nets, insecticides, and preventive antimalarial medications (newer options are effective and often have fewer side effects than older ones). But especially for people living in malaria-endemic regions, even the best prevention might not always succeed, and preventive medication is often not available long-term (and <em>Plasmodium</em> can develop resistance).</p><p>The good news is that malaria can be treated successfully, especially if diagnosed early.</p><p>Artemisinin, derived from sweet wormwood, a plant used in traditional Chinese medicine, is now a key component of malaria treatment. Scientist Tu Youyou received the Nobel Prize in 2015 for her role in discovering artemisinin as an effective, fast-acting treatment for malaria.</p><p>Artemisinin-based combination therapies, known as ACTs, include a fast-acting artemisinin derivative and a longer-lasting antimalarial drug, often one that was developed decades ago. The artemisinin derivative rapidly kills most parasites, while the second drug eliminates those that remain. Using two different drugs also helps reduce the development of resistance, which was a problem for older drugs used in the fight against <em>Plasmodium</em> and is also a concern for artemisinin.</p><p>Given that methods to prevent mosquito bites have their limitations, especially for people living in affected areas, and the risk of resistance development against prior and current treatment regimens, vaccination to help prevent infections is an important tool to further reduce malaria.</p><p>There are two vaccines recommended by the WHO for children living in malaria-endemic areas, and multiple currently under development. The two vaccines currently recommended target <em>P. falciparum</em>, more precisely, they target the sporozoite stage of <em>P. falciparum. </em>Quick reminder, sporozoites are injected by the mosquito and target liver cells to multiply. The vaccine prepares our immune system to counter this very first step. In comparison, naturally acquired immunity largely targets blood-stage parasites, which infect red blood cells.</p><p>Neither form of protection is complete, but clinical studies showed that the vaccines could reduce malaria episodes by more than 50% during the first year after vaccination (in fact, one of the two currently recommended vaccines showed a 67–75% reduction in symptomatic malaria cases during the first year). Protection declines over time, so additional vaccine doses are required to keep it up.</p><p>Using prevention, treatment and vaccination together provides powerful tools the WHO relies on for its goal to reduce malaria incidence and mortality rates by 90% by 2030 (relative to 2015). However, the 2024 figures show that, compared with 2015, malaria incidence rates increased by about 8%, while mortality rates decreased by only about 7%. This goal therefore remains far away. On the other hand, the large-scale rollout of malaria vaccines only began in 2024. By 2026, 25 African countries had introduced malaria vaccination into their childhood immunization programs, targeting more than 10 million children annually.</p><p><strong>In Summary</strong></p><p>Malaria is one of the world’s most serious infectious diseases. The vast majority of cases are in Africa, and young children are at highest risk of developing severe forms of the disease.</p><p>Modern treatments and vaccines provide tools to reduce infections, and ultimately deaths. Progress in vaccine effectiveness, availability and pricing will hopefully result in significant improvements.</p><p>While global malaria elimination is not yet on the horizon, there is hope that significant reductions in infections and deaths can be achieved.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d8f37eb0663c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Do We Really Need a Flu Shot Every Year?]]></title>
            <link>https://scienceworthknowing.medium.com/do-we-really-need-a-flu-shot-every-year-030bff153eb9?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/030bff153eb9</guid>
            <category><![CDATA[science-communication]]></category>
            <category><![CDATA[influenza]]></category>
            <category><![CDATA[influenza-vaccine]]></category>
            <category><![CDATA[public-health]]></category>
            <category><![CDATA[flu-vaccine]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Thu, 29 Oct 2026 18:28:33 GMT</pubDate>
            <atom:updated>2026-10-29T18:28:33.335Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M3KRZmZmpQzz453LkjBvig.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>The answer depends on where you live. No, not really, but kind of.</p><p>In the United States, the recommendation is for everyone aged 6 months and older to receive an annual flu shot (though the CDC advisory committee that normally reviews vaccination guidance has not met in 2026, leaving the previous recommendation in place). This recommendation has been in place since the 2010–2011 flu season.</p><p>In many countries in the European Union, annual flu vaccination is recommended for the elderly (typically starting at 60 or 65) and people with risk factors (including pregnant women), but not as widely as the US recommendation for everyone aged 6 months and older. Some European countries also recommend vaccination for healthy children.</p><p>The WHO recommendation is similar to those in Europe, but specifically includes children aged 6 months to 5 years, along with pregnant women, people over 65, people with chronic medical conditions, and healthcare workers.</p><p>So why do recommendations vary?</p><p>There isn’t one simple answer, as many countries have independent expert committees that provide the guidance. But given that the most vulnerable populations include young children, elderly people, pregnant women, and people with certain chronic medical conditions or weakened immune systems, recommending vaccination for these groups seems logical.</p><p>So why does the US provide a broader recommendation?</p><p>Influenza can infect all age groups, and having the flu is no fun, even without developing a more severe form. Additionally, the flu is highly contagious and can spread easily among unprotected populations. And given that many Americans have only limited paid sick leave, unlike in many European countries, people may drag themselves to work even when they have the flu, risking infecting others.</p><p>But instead of reading my speculations, let’s take a closer look at the influenza virus and the disease commonly referred to as the flu. We’ll return to the different vaccination recommendations later.</p><p><strong>What Is the Flu?</strong></p><p>The flu is short for influenza, which is a respiratory illness caused by influenza viruses. The virus is an RNA virus and spreads similarly to SARS-CoV-2 (the virus behind COVID-19), mainly through respiratory droplets and smaller airborne particles that are released when we cough, sneeze, talk, or even just breathe. So, if someone standing next to you has the flu, you may inhale some of those viral particles, which could be enough to cause an infection and make you come down with the flu.</p><p>Influenza is seasonal in temperate regions, circulating most widely during the winter months. Scientists have shown that the virus seems to spread more efficiently in cool, dry conditions, and humans tend to spend more time indoors, in closer proximity to each other, during the colder months.</p><p>I should make a quick statement on the word “flu”. When people say they have the flu, often they have “flu-like symptoms” that are actually not caused by the influenza virus (on that note, the expression “stomach flu” is not caused by influenza viruses; it is often caused by norovirus).</p><p>But back to the real flu, which has symptoms that often come on extremely quickly. One moment you feel fine, the next you do not. Fever or chills, a dry cough, sore throat, headache, and deep muscle aches can develop over a matter of hours, and people often feel extremely exhausted. And symptoms can last for days; a week is not uncommon. Of course, everyone is different, which means that not everyone shows all the symptoms, and for some the flu causes only very mild symptoms (which may also be due to some existing immunity, more below).</p><p>Most people, especially healthy adults, recover from the flu on their own, often after feeling miserable and exhausted for a week or so. However, especially young children and older adults (but also pregnant women and people with chronic conditions such as heart disease, diabetes, or asthma) are at elevated risk of developing more severe illness. One of the most important complications is pneumonia, an infection that causes inflammation of the air sacs in the lungs. Pneumonia can be caused by the virus itself or by a secondary bacterial infection.</p><p>For patients developing a more severe form of the illness, access to medical care can make an important difference. Treatment with specific antiviral medications, such as oseltamivir (Tamiflu), can shorten the duration of illness and may reduce complications, especially if started within 48 hours of symptom onset. For patients with severe illness, treatment may still be beneficial when started later. In hospital, patients can receive oxygen and other supportive care.</p><p>Some numbers help to show just how widespread the flu can be. During the 2024–2025 flu season, the CDC estimated around 51 million influenza illnesses in the United States. Roughly 710,000 people needed to be hospitalized, and tragically, about 45,000 people died. And the higher risk to the elderly is reflected in the numbers: adults aged 65 and older accounted for 57% of hospitalizations and 71% of deaths.</p><p>When talking about the virus, it is also important to highlight that there is not just one virus. There are two main types responsible for our annual flu seasons, influenza A and B. Influenza A has many subtypes, defined by their hemagglutinin (H) and neuraminidase (N) proteins, though only two of them, A(H1N1) and A(H3N2), currently circulate in people. These are different subtypes of influenza A, and immunity against A(H1N1) does not necessarily provide immunity against A(H3N2). Influenza B is also divided into different lineages, historically B/Victoria and B/Yamagata. B/Yamagata has not been detected anywhere in the world since March 2020, which is why current vaccines no longer include it.</p><p><strong>The Flu Vaccine</strong></p><p>The most widely used flu vaccines use inactivated influenza viruses, usually grown in chicken eggs. There are other vaccine types, such as recombinant vaccines (using only specific viral proteins, not the whole virus), and the latest is an mRNA-based vaccine, which I discuss in more detail in my article “<a href="https://medium.com/@scienceworthknowing/an-mrna-flu-vaccine-is-on-the-horizon-c2c70d544553"><strong>An mRNA Flu Vaccine Is Here</strong>.</a>”</p><p>But in this article, I want to focus on the fact that the flu vaccine is one of those vaccines that works, but not always as well as one would hope. And it’s worth explaining why this is the case, as there are rumors that the vaccine doesn’t work at all, and that’s not true.</p><p>Let’s start with how effective the vaccine usually is. According to CDC estimates, its effectiveness in preventing influenza illness that requires medical attention has usually fallen between about 40% and 60% in seasons when the vaccine is well matched to the circulating viruses. We will see below why there is such variation and sometimes even lower effectiveness (for example, the vaccine’s effectiveness in the 2014–2015 flu season was estimated to be only 19%).</p><p>This effectiveness reflects the vaccine’s ability to reduce the risk of laboratory-confirmed influenza illness that leads someone to seek medical attention. It does not directly measure the prevention of infection without symptoms or the prevention of severe illness, although vaccination can also reduce the risk of hospitalization and death. To understand the impact of the vaccine on the flu more broadly, let’s use the 2024–2025 season. Vaccination was estimated to have prevented around 10 million influenza illnesses, 180,000 hospitalizations, and 12,000 deaths in the United States alone.</p><p>While these numbers speak for themselves, why doesn’t the vaccine provide greater than 90% protection against influenza illness? And why is there a new vaccine every year? For comparison, two doses of the measles vaccine provide approximately 97% protection against measles disease, and for most people that protection lasts a lifetime, without the need for annual boosters.</p><p><strong>Why Is Influenza So Hard to Vaccinate Against?</strong></p><p>Influenza is not just one virus. This means that the seasonal flu vaccine needs to protect against several different influenza viruses. The standard combination in the vaccine has been A(H1N1), A(H3N2), and influenza B for years (since 2024–25 only B/Victoria), which are the viruses currently circulating. But the versions of each subtype (the strains) are different every year, or at least most years.</p><p>Influenza produces variations of itself as every so often random changes (mutations) are introduced when the virus copies its genome. This is very common for RNA viruses. These changes occur at random, and may not have any impact on the virus, or can even impair its ability to function. But these changes can also affect areas of the virus that are recognized by our immune system. These areas are called antigens, and if mutations impact the recognition by our immune system, it is called antigenic drift. This can mean that existing immunity is no longer fully effective against the changed virus.</p><p>But influenza A can also change more dramatically, very quickly. The viral genome is made of 8 separate RNA segments. And if two different influenza A viruses infect the same cell, new viruses can “mix and match” these segments, meaning the new virus may have 6 segments from one of the viruses, and the other 2 segments from the other virus. This process is called reassortment, and it can create a virus with a new combination of viral proteins and antigens. And if this leads to a substantial change in the viral antigens, it is called antigenic shift.</p><p>This process can also allow mixing of human and avian (or swine) influenza A viruses, if they infect the same cell. Non-human influenza A viruses usually don’t spread from human to human, so if they accidentally end up in a human, they stop there. But if they mix with a human influenza A virus, a new virus could emerge, and potentially cause the next pandemic. The 2009 H1N1 pandemic virus emerged from reassortment among influenza viruses circulating in pigs, with genes of human, avian, and swine ancestry.</p><p>These are all reasons why it is challenging to make a highly effective flu vaccine for every season. The virus can change quickly and without prior notice. Making the vaccine takes time, so scientists predict the influenza strains most likely to circulate next season, and the vaccine is made accordingly. But the virus actually circulating during the flu season can be different from the prediction, and sometimes the virus changes during the season itself.</p><p>There is hope that <a href="https://medium.com/@scienceworthknowing/an-mrna-flu-vaccine-is-on-the-horizon-c2c70d544553"><strong>mRNA vaccine technology</strong></a> might improve the match between the vaccine and circulating viruses, which I discuss in more detail in my earlier article. But this potential benefit has not yet been demonstrated.</p><p><strong>So, do I really need the vaccine every year?</strong></p><p>Health experts generally agree that anyone in a high-risk category should get the vaccine every year. For these groups, the benefits generally outweigh the risks.</p><p>Talking about risks, the most common side effects of inactivated influenza vaccines are soreness at the injection site, headache, fatigue, and muscle aches, which usually disappear within a few days. Serious reactions are possible, but extremely rare. Severe allergic reactions have been estimated at around 1–2 cases per million doses, and some studies have found a similarly small increased risk of Guillain-Barré syndrome, a neurological disorder that can cause muscle weakness and paralysis, usually with recovery over weeks to months.</p><p>It is also important to mention that febrile seizures have been observed in children aged 6 months to 4 years, about a day after vaccination. They are not linked to brain damage or later epilepsy, but parents need to be aware, as they can be extremely frightening to see. The excess risk has been estimated at 20 to 45 cases per million doses. On that note, the influenza virus itself can trigger the same seizures, and does so far more often.</p><p>For everyone not in the high-risk group, the vaccine still adds a protective layer. One <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/full">review</a> showed that the vaccine cut the risk of getting influenza roughly in half, confirming the vaccine generally works. But the same review also showed that only around 2% of unvaccinated healthy adults in those trials caught confirmed influenza in a season (this is from data including studies until 2016). Now, 2% of unvaccinated healthy adults can still be a lot of people.</p><p>Given all those factors, the EU recommended in 2009 that countries focus on the high-risk groups, older adults first, and reach 75% vaccination coverage in those groups, a goal the World Health Assembly had set in 2003. So far, as of 2022–2023, only four countries in Europe had reached that goal: Belarus, Denmark, Ireland and the United Kingdom.</p><p>The United States universal vaccine recommendation came in 2010. Before, vaccination was already recommended for children, all adults over 50, pregnant women, and anyone else at higher risk. In fact, vaccination was already recommended for the majority of people, so making it a universal recommendation just closed the gap. The committee also noted that people with risk factors often do not know they have one, and the vote came during the 2009 H1N1 pandemic, which had hit younger adults unusually hard.</p><p><strong>In Summary</strong></p><p>If you belong to one of the high-risk groups discussed earlier, vaccination can save your life. And even though the vaccine’s effectiveness varies greatly between years, it can still offer protection in a bad year. For example, during the 2014–2015 season, vaccination reduced the risk of influenza requiring medical attention by an estimated 19%. That means roughly one in five people who would otherwise have needed medical attention for influenza avoided it because of vaccination. This benefits those individuals, but also helps reduce the burden on hospitals, keeping medical care available for those who need it most.</p><p>For healthy adults, vaccination can still provide benefits, especially if new or substantially changed influenza strains are predicted to circulate. Previous infections or vaccinations may already provide some protection, including against severe illness. And even though many countries do not recommend annual vaccination for everyone, getting a flu shot may still be worthwhile, particularly if it is covered by health insurance or is available at an affordable price.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=030bff153eb9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[West Nile Virus]]></title>
            <link>https://scienceworthknowing.medium.com/west-nile-virus-bc34cb270aff?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/bc34cb270aff</guid>
            <category><![CDATA[west-nile-virus]]></category>
            <category><![CDATA[mosquito-borne-diseases]]></category>
            <category><![CDATA[virology]]></category>
            <category><![CDATA[infectious-disease]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Tue, 20 Oct 2026 21:33:36 GMT</pubDate>
            <atom:updated>2026-10-20T23:17:33.546Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xcsSmKtfbT3yZNKRp6yFlA.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>Mosquitoes are known to transmit viruses that can cause major outbreaks, affecting millions of people. Well-known examples include dengue, Zika, chikungunya, and yellow fever. Historically, these viruses have been associated with tropical and subtropical regions, but some are increasingly appearing in the United States and European countries, as I discussed in my earlier article on <a href="https://medium.com/@scienceworthknowing/dengue-a-growing-global-health-threat-604ac2cbfcb8">dengue</a>.</p><p>West Nile virus, another mosquito-transmitted virus, has long been established in the United States and parts of Europe, and it is making headlines right now. As of October 7, 2026, the European Centre for Disease Prevention and Control (ECDC) reported 1,715 locally acquired human infections and 130 deaths in the European Union. This makes 2026 the most intense West Nile season ever recorded in the EU, with Italy being particularly hard hit.</p><p>Some readers might wonder why they haven’t heard much about West Nile virus before, given that it has been around for such a long time. Others may have heard of it, but did you know that West Nile normally circulates between birds and mosquitoes, rather than humans and mosquitoes?</p><p>For anyone who wants to know more about West Nile virus, this article explains how the virus spreads, what happens when someone becomes infected, and what neuroinvasive West Nile disease is.</p><p>But before I start, here’s my usual disclaimer: this article is intentionally simplified. Its focus is on providing a basic understanding of West Nile virus rather than covering every scientific detail.</p><p><strong>What Is West Nile Virus?</strong></p><p>West Nile virus (WNV) was first identified in 1937 in the West Nile district of Uganda, which explains its name. Today, it is established in many parts of the world, including regions of Africa, Europe, the Middle East, Asia, and North America. In the United States, the virus was first detected in New York City in 1999. Since then, human infections have been reported in all 50 states, although sustained local transmission is established primarily across the 48 contiguous states.</p><p>West Nile virus is an RNA virus, meaning its genome is made of RNA rather than DNA. Other examples of RNA viruses include SARS-CoV-2 (the virus responsible for COVID-19) and dengue virus. WNV is actually related to dengue virus (but not SARS-CoV-2), as both belong to the family <em>Flaviviridae</em>, together with Zika and yellow fever viruses.</p><p>While both dengue virus and WNV use mosquitoes as vectors, their transmission cycles are quite different. Dengue primarily cycles between mosquitoes and humans, whereas West Nile primarily cycles between mosquitoes and birds.</p><p>A mosquito takes a blood meal from an infected bird and picks up the virus. The virus then multiplies inside the mosquito and can eventually be transmitted to another bird when the mosquito feeds again. And you guessed right, WNV then multiplies inside the newly infected bird, and the next mosquito feeding on that bird can pick up the virus.</p><p>The mosquitoes responsible for transmitting WNV belong mainly to the genus <em>Culex</em>, including <em>Culex pipiens</em>, a common mosquito species found across much of Europe and North America. These mosquitoes are particularly active around dusk and dawn.</p><p>But of course, these mosquitoes do not feed exclusively on birds. They also welcome a blood meal from other animals, including humans.</p><p>The “good news” is that most hosts other than birds are usually considered “dead-end hosts”: the virus can infect the host, but it will not be passed on to another mosquito feeding on that host.</p><p>This article will focus on what WNV can do to humans, although the virus can also cause serious illness in other animals, particularly horses.</p><p><strong>What Illness Does West Nile Virus Cause?</strong></p><p>Most people (approximately 80%) infected with West Nile virus will not experience any symptoms. They may have an itchy bite mark from the mosquito, but that’s it. They will not even know they have been infected with WNV, and the infection generally resolves on its own.</p><p>For the remaining ~20%, symptoms usually start anywhere between two and fourteen days after infection and may include fever, headache, muscle and joint pain, fatigue, nausea, and sometimes a skin rash. As these symptoms are not specific to WNV, patients often don’t realize what is causing them to feel unwell. In most cases, the illness resolves on its own. However, fatigue and weakness can sometimes continue for weeks or even months.</p><p>But unfortunately, WNV can also be much more serious. In fewer than 1% of all infections, the virus affects the central nervous system, causing what is known as <em>neuroinvasive West Nile disease</em>.</p><p>If this happens, the virus can cause meningitis (an inflammation of the membranes surrounding the brain and spinal cord) or encephalitis (an inflammation of the brain itself). The virus can also damage nerve cells responsible for muscle movement, resulting in muscle weakness or even paralysis.</p><p>Neuroinvasive West Nile disease is rare, but it can happen, and particularly adults over 60 and people with weakened immune systems or certain underlying medical conditions are at greater risk. The initial flu-like symptoms do not allow us to predict who will develop severe complications, and are often not even associated with WNV. Neurological complications can develop rapidly, sometimes within 24–48 hours of the first symptoms, although their onset varies between patients. Symptoms including high fever, severe headaches, a stiff neck, confusion, tremors, seizures, and muscle weakness are warning signs that require immediate medical attention.</p><p>Doctors can help confirm WNV infection using a blood test that detects antibodies against the virus. However, there is currently no specific antiviral treatment for West Nile virus. Treatment is supportive, but crucial in cases involving complications such as seizures and breathing difficulties. Recovery can take weeks or months, and some patients are left with long-term neurological problems. Unfortunately, according to the CDC, approximately 10% of patients who develop neuroinvasive disease die.</p><p>There are currently no vaccines available for humans, so protecting ourselves from mosquito bites (repellents, long sleeves, trousers) and keeping mosquitoes out of our homes using window and door screens are our best defenses.</p><p><strong>Why Is 2026 Such a Bad Year in Europe?</strong></p><p>This year has seen the highest number of reported West Nile infections on record in the EU. Belgium even reported its first locally acquired human infections.</p><p>Scientists believe that one important contributing factor is temperature.</p><p>Researchers have shown that cooler conditions slow down the process by which infected mosquitoes become capable of transmitting the virus to another host. Warmer temperatures accelerate this process, making transmission more efficient.</p><p>Warmer temperatures earlier in the year, combined with longer summer-like conditions, can also extend the period during which mosquitoes are active. This provides more opportunities for the virus to circulate between birds and mosquitoes.</p><p>Another piece of the puzzle may be improved surveillance. The exact reasons for Europe’s unusually high number of reported cases in 2026 are not yet known. However, the ECDC expects West Nile to continue spreading into northern Europe.</p><p><strong>In Summary</strong></p><p>West Nile virus is not a new virus, and it has caused outbreaks before.</p><p>For the vast majority of people infected, the infection either goes completely unnoticed or causes only flu-like symptoms. However, a small percentage develop serious neurological disease, which can be fatal.</p><p>As we currently have no vaccine for humans and no specific antiviral treatment, understanding how the virus spreads, monitoring its circulation, and preventing mosquito bites remain our best defenses.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bc34cb270aff" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[HIV: The Virus, the Treatment, and Resistance]]></title>
            <link>https://scienceworthknowing.medium.com/hiv-the-virus-the-treatment-and-resistance-12deb0c03a35?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/12deb0c03a35</guid>
            <category><![CDATA[drug-resistance]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[aids]]></category>
            <category><![CDATA[hiv]]></category>
            <category><![CDATA[hiv-awareness]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Sat, 17 Oct 2026 16:33:26 GMT</pubDate>
            <atom:updated>2026-10-17T16:33:26.948Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*QspMZuIUq0zZYC2f9XmZlw.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>A lot has changed since the disease caused by the Human Immunodeficiency Virus (HIV) was officially named AIDS (Acquired Immunodeficiency Syndrome) in 1982. Even though the scientific tools available in the 1980s were nowhere close to today’s technology, researchers at the Pasteur Institute in France, including Luc Montagnier and Françoise Barré-Sinoussi, identified in 1983 the new retrovirus that causes AIDS. Both scientists were awarded the Nobel Prize in 2008 for their discovery of HIV.</p><p>The virus was later given the name Human Immunodeficiency Virus, reflecting its ability to weaken our immune system. It does so primarily by infecting CD4+ T helper cells, which are crucial for coordinating the body’s immune response. As the virus replicates, these cells are progressively depleted, weakening our immune system over time.</p><p>Once the immune system has become severely weakened, opportunistic infections or cancers can overwhelm our body, as there is no longer an adequate defense. This is when the advanced stage of HIV infection, Acquired Immunodeficiency Syndrome (AIDS), can develop. HIV itself can cause flu-like symptoms shortly after infection, but these symptoms usually disappear, and people infected can live without noticeable symptoms (often for years) while the virus slowly and continuously weakens their immune system. Without treatment, an infection with HIV usually (with very few exceptions) leads to AIDS and ultimately can cause death from opportunistic infections or cancers.</p><p>The good news is that, with the medications available nowadays, HIV-positive people can live long, healthy lives and never develop AIDS. Today’s medications cannot fully remove the virus from our bodies, but they can suppress its replication enough that it becomes undetectable in standard blood tests.</p><p>It has been a long way to get to where we are now. An estimated 44 million people have died from AIDS-related illnesses since the early 1980s, and intensive educational campaigns, preventive measures, and scientific and medical breakthroughs were needed to slow down the spread of the virus and transform a once deadly infection into a manageable chronic condition that allows people to live long and healthy lives. At least for people who have access to medication.</p><p>And that is also one of the major challenges we face. Not everyone has access, and not everyone who was on medication remains on medication.</p><p>We have come a long way, but challenges remain. So, let’s look at the virus and its current treatment a little closer to understand why it is on us to keep HIV at bay.</p><p>But before I start, here’s my disclaimer: this article is intentionally simplified. This article’s focus is on a basic understanding of HIV and treatment. The article also refers to DNA (deoxyribonucleic acid), the chemical substance our genome is made of. In our cells, specific areas of the DNA can be copied into RNA, including messenger RNA (mRNA), which is used by the cell to make the final product, the protein. Proteins that catalyze chemical reactions, such as copying DNA into RNA, are called enzymes.</p><p><strong>HIV — The Virus</strong></p><p>HIV is a retrovirus, which means it carries an RNA genome in its viral particle, similar to SARS-CoV-2 and influenza viruses. Unlike these viruses, HIV copies its RNA into DNA during infection. Another difference is that the HIV viral particle contains two copies of its RNA genome.</p><p>HIV not only brings two copies of its RNA genome when it infects a cell, but also two important viral enzymes. One is called <em>reverse transcriptase</em>. This enzyme copies the viral RNA into DNA, reversing the usual flow of genetic information in our cells. The viral DNA is then integrated into our cellular genome by the second enzyme, which is called <em>integrase</em>. Once integrated, the viral DNA is called a <em>provirus</em>. I want to highlight what I just described: the viral genetic information is not just in our cell, but it becomes part of our own genome.</p><p>The viral DNA in our genome is then used to make new viral RNA copies. Some RNAs are copies of the full-length viral genome, while others are processed into shorter RNAs containing only certain parts. It’s complicated. Either way, the RNA is used to make more viral proteins. Some of the full-length RNA copies (containing all the viral information) are also packaged into new viruses that are released from the cell to infect other cells.</p><p>I just want to point out that when the infected cell multiplies, the human genome is copied, and that includes a copy of the provirus. Meaning, both daughter cells will contain HIV DNA.</p><p>As this chapter is about the virus, there are two main virus types: HIV-1 and HIV-2 (both are members of the <em>Lentivirus</em> genus within the retrovirus family). Within these types, there are different genetic groups, and HIV-1 includes several subtypes and recombinant forms.</p><p>HIV is a very diverse virus. HIV-1, group M (Major), is responsible for the overwhelming majority of infections worldwide. Its various subtypes have different prevalence rates across regions of the world.</p><p><strong>HIV Transmission and Diagnosis</strong></p><p>It’s always helpful to quickly recap how the virus is transmitted and how it can be detected.</p><p>HIV is transmitted through sexual contact, exposure to infected blood (for example, sharing needles or other injection equipment), and from mother to child during pregnancy, birth, or breastfeeding. These routes carry the highest risk when HIV is not effectively suppressed. The chapter “HIV Treatment” will discuss how medication affects transmission.</p><p>With that in mind, it is important to know whether one is HIV-positive. That knowledge is the first step toward starting treatment. So, if there is any reason to suspect an infection with HIV, please get tested. A diagnostic test is the only way to know.</p><p><strong>HIV Treatment</strong></p><p>The first treatment became available in 1987, just a few years after the virus was discovered, which is remarkably fast. It was a drug called AZT (zidovudine), which interferes with the viral reverse transcriptase enzyme, blocking the virus from copying its RNA into DNA. Unfortunately, the virus was quickly able to evolve and develop resistance to the drug.</p><p>Modern HIV treatment generally uses effective combination therapy, often targeting at least two different steps in the viral replication cycle. This is crucial to strongly suppress the virus and make it much harder for resistance to develop. Simply put, using one drug may not fully stop the virus from copying itself, and if only one new copy has a mutation that allows the virus to resist that one drug, the virus wins. Using multiple drugs suppresses HIV more effectively and may fully stop the virus from copying itself, preventing new mutations from arising. And if the virus is still able to make a few copies, it would need the right mutations to overcome the antiviral effects of the combination. Given that mutations occur at random, this is very unlikely to happen. But unfortunately, on rare occasions and under the right circumstances, it can happen. More about this in the chapter “HIV Drug Resistance” below.</p><p>Talking about HIV drug resistance, in the United States the virus is usually tested for known resistance mutations (genotypic resistance testing) when a patient is first diagnosed. Patients generally begin a recommended first-line regimen without waiting for the results, as starting treatment as soon as possible is important. The treatment can be adjusted if resistance is identified or treatment does not work as expected (see viral load testing below).</p><p>One commonly used antiretroviral therapy (ART) approach in the United States combines drugs that block the viral reverse transcriptase and integrase. Other medications can target the viral protease or the viral capsid, the protein shell surrounding the viral genetic material.</p><p>Many antiretroviral therapy (ART) regimens require patients to take pills every day, sometimes just one combination tablet, whereas long-acting treatments allow some patients to receive injections every one or two months instead.</p><p>It is crucial to regularly confirm that treatment is working and the virus is suppressed. This is done by measuring the amount of HIV RNA in a blood sample, called the <em>viral load test</em>. With successful viral suppression, the virus can become undetectable in the blood. People who maintain viral suppression do not sexually transmit HIV to their partners. This is known as U=U, or Undetectable = Untransmittable.</p><p>It is worth calling out that maintained viral suppression does not only prevent sexual transmission of HIV, but also dramatically reduces the risk of transmission from mother to child. With effective treatment and a suppressed viral load throughout pregnancy and childbirth, the risk of transmitting the virus to the child is one percent or less (compared to an estimated 15–45% risk without treatment or other interventions). The risk during breastfeeding can also be reduced to less than one percent, but is not zero.</p><p>On that note, the virus being undetectable does not mean that it has been cleared from the body. Unfortunately, the virus still exists as DNA integrated into the genome of infected cells and can become active again if treatment is stopped (or resistance develops). That’s why the blood-based viral load test is generally performed every three to six months once viral suppression has been achieved and remains stable.</p><p>Antiretroviral medications can also be used as <em>pre-exposure prophylaxis</em> (PrEP), in which HIV-negative individuals take the medication to protect themselves from a potential infection. For example, someone who has sexual contact with partners whose HIV status is unknown could benefit from PrEP.</p><p>There is also <em>post-exposure prophylaxis</em> (PEP), which can prevent infection after a potential exposure to HIV. PEP must be started as soon as possible, no later than 72 hours after exposure, and the medication must be taken for 28 days.</p><p><strong>HIV Drug Resistance</strong></p><p>I highlighted above that people managing HIV with antiretroviral therapy should have the virus tested for known resistance mutations when starting treatment and undergo regular viral load testing.</p><p>The good news is that developing new resistance to today’s drugs is extremely uncommon if a person adheres to the treatment plan. But a person could be infected with a virus that is already resistant to the standard first-line treatment (transmitted drug resistance), hence the assessment of the virus at the beginning of treatment.</p><p>As stated above, once successful treatment is initiated, the virus is very unlikely to develop resistance. First, an effective drug regimen suppresses viral replication very efficiently. Mutations that could create resistance can only happen when the virus replicates; in other words, little or no replication means few or no new mutations. And second, newer drugs are designed to have a high “genetic barrier to resistance,” meaning the virus generally needs to acquire several specific genetic changes to counter the impact of the drug, which makes resistance even less likely. Additionally, mutations happen randomly, so acquiring the right combination of changes needed to overcome the effects of the drugs is much less likely.</p><p>This also means that the risk of resistance developing increases with increased viral replication. Imagine a patient who has prolonged periods of inconsistent medication use (repeatedly missing doses or taking less medication than prescribed), or a patient who is also taking other drugs for a different medical problem, and these drugs negatively interact with the HIV drugs. Both cases can reduce the concentration or effectiveness of the antiviral regimen, which can allow viral replication to increase. Any randomly acquired mutation that gives the virus a benefit against the medication still present could allow that variant to replicate more effectively and emerge as a resistant strain.</p><p>Stopping medication altogether can also create a risk of developing resistant strains. One might think that once the patient no longer takes medication, the virus simply starts replicating without needing to develop drug resistance, and the patient may eventually develop AIDS (unless effective treatment is restarted). The problem is that medication does not necessarily disappear from the body overnight. Some long-acting HIV drugs can stay in the body for months, and drug concentrations decline over time, potentially allowing viral replication while some drug is still present. This can increase the risk that the virus develops resistance.</p><p>And resistance is real. HIV strains that are resistant to many of the available antiretroviral medications have emerged, including strains that are resistant to multiple drugs at once (multidrug-resistant HIV). Resistance has also been found against drugs with a high “genetic barrier to resistance,” even against the newest drugs that haven’t been on the market that long. That doesn’t mean that we are at risk of losing the fight against HIV, but it shows what is biologically possible and that we have to do everything we can to prevent the emergence and spread of resistant HIV strains.</p><p>Please note, this is highly simplified and meant to provide a general understanding of the problem.</p><p><strong>HIV Needs to Be Fought Worldwide</strong></p><p>When discussing HIV, the current circumstances demand that we talk about the sudden disruption of international HIV programs supported through USAID and PEPFAR. USAID was a substantial source of HIV medication, testing, and preventive measures, including condoms. The World Health Organization (WHO) has warned that loss of funding could reverse decades of progress in fighting HIV, putting millions of people at risk of illness and death.</p><p>I also want to call out a concern that <a href="https://www.who.int/news-room/questions-and-answers/item/guidance-on-handling-interruptions-in-antiretroviral-treatment-due-to-hiv-service-disruptions--drug-shortages--or-stockouts">WHO</a> has raised explicitly: when drug supplies become unreliable, people may take their medication inconsistently or stretch what they have left, for example by skipping days or taking only part of a regimen. WHO warns that this may increase the risk of developing drug resistance. And as the loss of funding also affected viral load testing, treatment that is failing or has stopped working may go unnoticed. These are conditions that create a risk for new resistant strains to emerge.</p><p>It remains to be seen what happens, but as I stated above, “we have to do everything we can to prevent the emergence and spread of resistant HIV strains.”</p><p><strong>Where Does That Leave Us?</strong></p><p>HIV treatment is one of the great achievements of modern medicine. It offers an almost normal life to people with a disease that just a few decades ago was a death sentence.</p><p>But resistant strains already exist, and HIV has developed resistance to many available medications, including some newer drugs. Fortunately, effective treatment options remain available for most patients, including those infected with HIV strains resistant to certain medications.</p><p>But at the same time, we need to take steps to stay ahead of the virus. Patients need to get medication that is effective against the HIV strain(s) they are infected with, access to medication needs to be uninterrupted, the medication needs to be taken as prescribed, and regular testing is crucial to confirm that treatment is successful.</p><p>With that in mind, I repeat the most important sentence from this article: “…if there is any reason to suspect an infection with HIV, please get tested. A diagnostic test is the only way to know.” And if you have recently been exposed to HIV, contact your physician immediately to discuss PEP.</p><p>.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=12deb0c03a35" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can a blood test screen for more than 50 types of cancer? Understanding Galleri]]></title>
            <link>https://scienceworthknowing.medium.com/can-a-blood-test-screen-for-more-than-50-types-of-cancer-understanding-galleri-d0df50ad92fc?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/d0df50ad92fc</guid>
            <category><![CDATA[cancer-screening]]></category>
            <category><![CDATA[liquid-biopsy]]></category>
            <category><![CDATA[galleri]]></category>
            <category><![CDATA[mced]]></category>
            <category><![CDATA[early-detection-cancer]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Tue, 13 Oct 2026 03:26:32 GMT</pubDate>
            <atom:updated>2026-10-13T03:26:32.502Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Nz2SeyE1CioUnjZre2fWhA.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>I have previously published an article on the concept of liquid biopsy (“<a href="https://medium.com/@scienceworthknowing/understanding-liquid-biopsy-534ffb665643"><strong>Understanding<em> Liquid Biopsy</em></strong></a>”), and how a simple blood draw can be used to look for disease-related signals, using cancer as an example, without the need for more invasive sampling. In fact, some liquid biopsy approaches may even detect cancer signals before traditional tests would.</p><p>Now, imagine there is one test that can screen for more than 50 types of cancer, many of which aren’t regularly screened for, and that the test may also detect some cancers at an early stage. And all that is needed from the patient is a blood sample. And remember, despite the development of newer treatments for cancer, detecting cancer early remains one of the most important factors in improving treatment options and outcomes.</p><p>A test that can do this using just a blood sample almost sounds too good to be true. But that is exactly what Galleri was developed for. It has been submitted to the FDA for premarket approval and is currently under review.</p><p>So how does the test work? And how well does it perform? Can it really screen for more than 50 different cancers, including at early stages?</p><p>Let’s take a closer look.</p><p>And as always, here’s my disclaimer: this article is intentionally simplified. This article’s focus is on understanding how Galleri works and how well it performs.</p><p>.</p><p><strong>What Is Galleri?</strong></p><p>As stated above, Galleri is a multi-cancer early detection, or MCED, test. Instead of screening for only one cancer, Galleri looks for signals in a blood sample that can be associated with more than 50 different cancers.</p><p>The test works a little differently from the liquid biopsy tests I explained in my article Understanding Liquid Biopsy. Galleri also analyzes cell-free DNA (cfDNA) and uses next-generation sequencing (NGS), but it does not look at mutations in the DNA sequence as markers for cancer. Instead, it analyzes methylation patterns in cfDNA. Methylation marks are small chemical tags that can be added to and removed from DNA (without changing the DNA sequence itself). They help regulate gene activity, and cancers often have characteristic methylation patterns.</p><p>If you have never heard of methylation, my article <a href="https://medium.com/@scienceworthknowing/epigenetics-in-personalized-medicine-68c04a34cd6c"><strong><em>Epigenetics in Personalized Medicine</em></strong></a> explains DNA methylation and its role in cancer diagnostics in more detail.</p><p>Galleri is designed to detect methylation patterns associated with more than 50 different cancers and, if a cancer signal is detected, predict where in the body that signal most likely originated. That information can then be used to follow up with more specific diagnostic testing to confirm Galleri’s findings.</p><p>There is one more important fact about the Galleri test. It is designed to test asymptomatic people, meaning people who do not show signs or symptoms of cancer. It is therefore a screening test, and any positive result must be followed by an appropriate diagnostic work-up to confirm or rule out cancer. Additionally, it is for adults aged 50 years or older and should be used on top of existing recommended cancer screening tests. It is not a replacement for mammography, colorectal cancer screening, cervical screening, appropriate lung cancer screening, or other recommended tests. But many of the cancers Galleri tests for do not currently have a routine screening test.</p><p>.</p><p><strong>Does Galleri Deliver?</strong></p><p>This is where it gets (even more) complicated. The FDA is currently reviewing Galleri’s premarket approval application, with results from two large clinical studies: PATHFINDER 2 in North America and NHS-Galleri in England. Together, roughly 180,000 people were enrolled in the studies.</p><p>Both studies produced very similar results. In PATHFINDER 2, sensitivity was 35.0% and specificity was 99.85%. In NHS-Galleri, sensitivity was 31.6% and specificity was 99.74%.</p><p>But what does this mean?</p><p>Clinical sensitivity describes how many people with cancer were actually detected as positive for cancer by Galleri. The reported sensitivity means that only about every third person with cancer was identified as having cancer by Galleri.</p><p>Before discussing whether 31–35% sensitivity is good, let’s understand specificity first. In both studies, specificity was over 99%, and that is good, as it means that only very few people without cancer were falsely predicted to have cancer by Galleri. And here you have to keep in mind, Galleri is a screening test, so if Galleri falsely indicates cancer, follow-up testing can clarify the result.</p><p>Now back to the 31–35% sensitivity. This number makes it sound like Galleri is missing a lot of cancer patients, but one has to keep in mind Galleri is trying to find cancers that would otherwise stay hidden, and achieving this in about one third of the patients could easily be seen as a huge success. It certainly feels better than the cancer not being detected.</p><p>Another number to consider is the positive predictive value, or PPV. This number states how often a patient with a cancer-positive Galleri test result actually has cancer. The PPV was 66.2% in NHS-Galleri and 77.0% in PATHFINDER 2, meaning that about two-thirds to three-quarters of patients with a cancer-positive Galleri test actually had cancer. This number is important, as a positive Galleri result creates anxiety and requires follow-up testing.</p><p>And if this isn’t already complicated enough, it is important to look at how the study was designed. For the performance analysis, participants with a Galleri result were followed for one year to determine if cancer was diagnosed. This can mean that Galleri might have detected cancer early, but that cancer could not be confirmed within a year from Galleri’s result. It could also mean that Galleri missed detecting a cancer for someone who actually had cancer, but wasn’t diagnosed until after the 12-month window.</p><p>Coming back to the question “does Galleri deliver?” The FDA is currently deciding the very same question.</p><p>.</p><p><strong>Galleri Does Not Detect Every Cancer Equally</strong></p><p>Cancer is complicated. And Galleri does not detect all the cancers it is designed to detect with the same sensitivity reported above.</p><p>Both studies had results in favor of Galleri, as the sensitivity to detect the 12 cancers that are responsible for about two-thirds of cancer deaths in the United States was actually higher (which is good). It was 52.1% in NHS-Galleri and 61.3% in PATHFINDER 2, so more than half of patients with these cancers were correctly identified by Galleri as such.</p><p>This is of interest, as cancers in this group include cancers that currently do not have a routine screening test (such as pancreatic, ovarian and liver cancers). Galleri, if approved, could provide an FDA-approved screening option for these cancers.</p><p>But not all results were in favor of Galleri. Detection rates varied widely between individual cancer types. In both studies, Galleri found around 80% of liver and bile duct cancers, but only about 11% of prostate cancers. This difference could be due to the cancer type, the stage the cancers were in, or both.</p><p>Galleri is generally better at detecting later-stage cancer than very early cancer, which is not surprising. Tumors are bigger or more advanced at a later stage, resulting in more tumor DNA being released into the blood, which makes it easier to detect with a liquid biopsy test. To illustrate this with numbers, one NHS-Galleri analysis found that the sensitivity to detect early-stage cancer (stage I) was only 13.6%, whereas late-stage cancer (stage IV) had a sensitivity of 60%.</p><p>Just looking at the numbers, that would make Galleri less of an early-stage cancer detection test, but the NHS-Galleri trial included one more set of results. Galleri is a screening test, and most screening tests are not one-time-and-done tests. Most screening tests are meant to be repeated regularly.</p><p>In the NHS-Galleri trial, people in the Galleri group got not one Galleri test done, but up to three, one per year over three years. The idea of testing once per year is to catch a cancer while still in the early stage. Even if the first year’s testing misses a stage I cancer, one of the follow-up tests will hopefully detect that cancer before it reaches a later stage. The results of the trial showed about 14% fewer patients with stage IV cancer in the Galleri group over the three years, compared to the control group. However, the trial did not meet its primary goal.</p><p>.</p><p><strong>In Summary</strong></p><p>Galleri is intended to be a screening test for people who have no symptoms or other reasons to believe they have cancer.</p><p>Having a test that detected cancer in about one-third of the people with cancer before they had symptoms or other reasons to suspect cancer could be seen as a step forward.</p><p>Having a test that can detect cancers for which we currently do not have a routine screening test could be seen as a step forward.</p><p>But there are other questions that need to be evaluated. What is the real value of Galleri, given that its best performance is with late-stage cancers? If Galleri detects cancer signals, how does this change the outcome for the patient? And let’s face it, there is also a financial aspect and insurance companies will want answers before covering a potential annual screening test (see my article about <a href="https://medium.com/@scienceworthknowing/what-does-clinical-utility-mean-7e29857cab35"><strong>clinical utility</strong></a>, where I discussed the difference between demonstrating that a diagnostic test works and showing that using it improves healthcare, including financial aspects).</p><p>Either way, this test is definitely worth our attention.</p><p>.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d0df50ad92fc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Understanding Rabies and Why Treatment Has to Start Before Symptoms Do]]></title>
            <link>https://scienceworthknowing.medium.com/understanding-rabies-and-why-treatment-has-to-start-before-symptoms-do-72d5bebf5152?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/72d5bebf5152</guid>
            <category><![CDATA[rabies]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Fri, 25 Sep 2026 22:26:56 GMT</pubDate>
            <atom:updated>2026-09-25T22:26:56.244Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>Understanding Rabies and Why Treatment Has to Start Before Symptoms Do</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*hHaCAFpWXQapTjrUMNbvhA.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>Rabies can be a deadly disease. The World Health Organization estimates that it causes tens of thousands of deaths each year. In the United States, only very few people die of rabies each year, but that does not mean that rabies does not exist here. In fact, rabies in animals is more common in the United States than most people realize.</p><p>In August 2026, two beavers that tested positive for rabies attacked visitors at Cunningham Falls State Park in Maryland. Just a few weeks later, health officials in North Carolina confirmed rabies in baby goats from a traveling petting zoo, potentially exposing hundreds of people who had interacted with them. And these were not isolated events. Similar reports of people being exposed to rabid or potentially rabid animals were coming from multiple parts of the country. On September 10, the CDC issued a nationwide health advisory as rabies-related inquiries and treatments had increased.</p><p>Rabies is endemic in wildlife in the United States, but why do so few people die of the disease here, whereas in other countries so many more do? Let’s take a closer look at rabies: what it is, where it is found, how people get infected, and what can be done after an exposure.</p><p><strong>What Is Rabies?</strong></p><p>Rabies is caused by the rabies virus, which has a genome made of RNA. Just as a reminder, our genome is made of DNA, which needs to be copied into RNA before proteins can be made.</p><p>Viruses such as SARS-CoV-2, the virus that causes COVID-19, have an RNA genome that can be used directly to make viral proteins. The RNA genome of rabies virus cannot. It contains all the genetic information, but in a kind of mirror-image, or complementary, version of the instructions. Rabies virus therefore has what is called a minus-strand RNA genome. Its genetic information needs to be copied into a plus strand, which can then be used to make the viral proteins.</p><p>Rabies can infect all kinds of mammals, including dogs, cats, bats, raccoons, foxes, skunks, and, of course, humans.</p><p>The virus is transmitted through the saliva of an infected animal, most commonly through a bite. But even a scratch can transmit rabies if it is contaminated with infected saliva. An infection is also possible if contaminated saliva comes into contact with the mucous membranes of the eyes, nose, or mouth.</p><p>The virus then enters the peripheral nerves and slowly “travels” along the nervous system toward the spinal cord and brain. Once the virus reaches the brain, the first symptoms can be nonspecific and include fever, headache, weakness, and generally feeling unwell. Some people develop pain, tingling, itching, or an unusual sensation around the original bite site.</p><p>However, within days, more obvious neurological symptoms follow. These can include anxiety, confusion, agitation, hallucinations, and seizures. Difficulty swallowing is common, and rabies can also cause excessive saliva production. For some patients, swallowing can trigger extremely painful, involuntary spasms of the throat and swallowing muscles, which can lead to a symptom called hydrophobia, literally “fear of water.” But the fear is caused by the pain associated with swallowing. Eventually, the connection becomes so strong that even the sight or thought of water can trigger these spasms</p><p>Some patients develop a different form of the disease, in which weakness and paralysis gradually spread through the body. This form is called paralytic rabies.</p><p>Unfortunately, once a patient starts to show symptoms, rabies is almost always fatal.</p><p>The good news is that there is an incubation period between the time of infection and the onset of symptoms. While the length of this period can vary, it often takes weeks to months. Starting treatment before symptoms appear can stop the virus, and treatment should be started as soon as possible.</p><p><strong>Treatment of Rabies</strong></p><p>If there is a bite or scratch from an animal suspected to have rabies, the first step is to thoroughly wash the bite or wound with soap and water, to physically remove virus from the wound and reduce the amount present at the exposure site.</p><p>The next step is called post-exposure prophylaxis, or PEP. For people who have not previously been vaccinated, it consists of two treatment components: antibodies against rabies and the rabies vaccine. People who have previously been vaccinated still need treatment, which consists of additional vaccine doses.</p><p>The antibodies are injected into and around the wound, as this is where the virus has entered the body. Just like the antibodies our own immune system produces, these antibodies (referred to as human rabies immune globulin, or HRIG) specifically bind to the rabies virus, and by doing so can neutralize the virus. Giving HRIG at the start of treatment provides antibodies much quicker than waiting for the body’s immune response to make them. But our own immune response is crucial to stop rabies.</p><p>This is why the second component is a rabies vaccine. It teaches your own immune system to recognize the virus and produce its own protective response, but this takes time. HRIG bridges that gap.</p><p>Now, why does vaccination work after infection has already happened?</p><p>In rabies, this works because the virus needs time to get from the infection site to the central nervous system. This time allows our immune system to develop a strong protective response against the rabies virus after vaccination. And this is also the reason why treatment needs to start as soon as possible, to allow our immune system to develop an effective response before the virus gets to the central nervous system.</p><p>In fact, if treatment is started promptly, rabies is almost completely preventable. Once symptoms begin, however, the disease is almost always fatal.</p><p><strong>Which Animals Can Spread Rabies?</strong></p><p>In the United States, rabies is now found primarily in wildlife, particularly bats, raccoons, skunks, and foxes.</p><p>Routine vaccination of domestic dogs in the United States has made rabies in dogs extremely uncommon. This is worth mentioning because dogs are responsible for most human rabies cases worldwide.</p><p>In the United States, bats are the leading cause of human rabies deaths. A bat bite can be extremely small and may not leave an obvious mark. If you wake up and discover a bat in your bedroom, it is important to contact your local health department or a healthcare provider for a rabies risk assessment. You may have been bitten without even noticing it.</p><p><strong>What Does Rabies Look Like in an Animal?</strong></p><p>The first image that comes into my mind is an aggressive animal foaming at the mouth. While that can be the case, rabies does not always look like that.</p><p>As the virus affects the brain and nervous system, an infected animal may behave strangely. A normally shy wild animal might suddenly approach people. The animal may have difficulty walking or show other signs of impairment. And yes, an animal may also become unusually aggressive.</p><p>But a rabid animal can also be on the quiet side. It can be extremely difficult, next to impossible, to reliably tell whether an animal has rabies just by looking at it.</p><p>It is always best to avoid contact with wild animals. Best for you. Best for the animal.</p><p><strong>In Summary</strong></p><p>Rabies occurs on every continent except Antarctica, although some countries have successfully eliminated the virus or dog-mediated rabies. In the United States, human rabies deaths are rare because rabies in dogs is uncommon and treatment is readily available.</p><p>If you are bitten or scratched by a wild or unfamiliar mammal, or may have had contact with a bat, wash the wound and contact a healthcare provider or local health department. Rabies is almost always fatal once symptoms begin, but it is also highly preventable if treatment starts in time.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=72d5bebf5152" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What are Molecular Glues?]]></title>
            <link>https://scienceworthknowing.medium.com/what-are-molecular-glues-3eeb3b617ac6?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/3eeb3b617ac6</guid>
            <category><![CDATA[drug-discovery]]></category>
            <category><![CDATA[iberdomide]]></category>
            <category><![CDATA[rasonque]]></category>
            <category><![CDATA[molecular-glue]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Fri, 04 Sep 2026 14:23:46 GMT</pubDate>
            <atom:updated>2026-09-04T14:23:46.238Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IzSrIrZ6AvOapXjx0UozBg.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>On 26 August 2026, the FDA approved Rasonque (daraxonrasib), a new drug to fight metastatic pancreatic cancer. This new drug binds to a target that has long been deemed to be undruggable. And in doing so, a Phase III clinical trial in patients who had already had another treatment showed that the drug doubled the median survival time from 6.7 months to 13.2 months. It is not a cure, but it is a huge step forward in fighting metastatic pancreatic cancer.</p><p>Rasonque is a molecular glue. That is not just a fancy scientific wordplay; it is literally a glue: it sticks two molecules together. In the case of Rasonque, it “glues” cyclophilin A (CypA) to RAS. Another molecular glue that was also approved in August 2026 by the FDA is Iberdomide (Zenbexus), used to treat multiple myeloma. This glue brings cereblon (CRBN) to either IKZF1 or IKZF3, two proteins that myeloma cells depend on. I will explain below what that all means.</p><p>The concept of molecular glues is not new, and there are several approved drugs in this category. Some older drugs were only recognized as molecular glues after they were already in use. Rasonque and Iberdomide were intentionally developed as molecular glues.</p><p>So, what exactly are molecular glues?</p><p>But before I start, here’s my disclaimer: this article is intentionally simplified. This article’s focus is on understanding molecular glues and how they are being used.</p><p>.</p><p><strong>Understanding Molecular Glues</strong></p><p>A lot of drugs are designed to bind to a specific target, which is often a protein. The drug physically interacts with that target, and this interaction changes what happens in the cell or body. Maybe the interaction most people know of is the binding of an antibody to its target, called an antigen. Our immune system uses antibodies to recognize and bind to specific foreign molecules, which can be a first step in neutralizing a threat or helping the immune system remove it. An antibody against SARS-CoV-2, for example, can bind to the viral spike protein, which the virus needs to enter and infect a cell. Additionally, antibodies can mark the virus for other components of the immune system to recognize and destroy.</p><p>Antibodies can also be used as drugs. When the target is a protein, antibodies recognize and bind to a specific area of the target, called an epitope, based on the amino acids present and, in many cases, the structure formed by those amino acids. Proteins are made of amino acids, which are joined in a specific order, and these amino-acid sequences fold into three-dimensional structures.</p><p>But antibodies are considered large molecules, and they are generally too big to get into a cell. Antibody drugs usually bind to targets on the cell surface, or to other molecules outside cells.</p><p>Smaller drugs that can get into the cell are referred to as small-molecule drugs. Many of these drugs can pass through the cell membrane because of their small size and chemical properties, such as charge and polarity. Once inside the cell, these drugs can bind to their target. Small molecules usually bind to a specific pocket, groove, or cavity on a protein that matches the shape of the drug. Additionally, the chemical and physical interactions between the drug and its target also need to work. Several different types of forces can be involved, and the details can get quite complicated. For example, amino acids can contain positively or negatively charged groups, and the drug needs to have the right properties at the correct position to allow stable binding. And remember, the drug is usually sitting inside a pocket. Not only must the shape fit, but many of the surfaces surrounding the drug can interact with it. This creates a relatively large area of contact between the drug and its target and helps create a stable connection. Think of it a little bit like a key (the drug) that needs to have the right size and structure to fit into the lock (the pocket), while the different parts of the key also need to line up with the pins inside the lock.</p><p>But what if the target doesn’t have a pocket, groove, or cavity?</p><p>A small-molecule drug might not be able to bind strongly enough to the target, as only a small surface area of the drug could make direct contact with the relatively flat surface of the target. Even if the chemical and physical interactions align, there is often not enough contact for a stable connection. But what if there were a way to increase the surface area involved in binding to the target?</p><p>And that is what molecular glues do, in a way. Molecular glues are like a fitting puzzle piece placed between two other pieces that do not yet fit together. Once the molecular glue binds, they can be connected. Imagine there is another protein that has a pocket, and the molecular glue fits perfectly into that pocket. The glue sits in the pocket, but some of the glue’s surface is still sticking out, and it is now “extended” by the surrounding surface of the protein containing the pocket.</p><p>This “extended” surface can now bind to the actual target. Binding of the molecular glue can also change the shape or properties of the protein surface. If the shape and chemical properties of this new surface match the target, the whole complex can bind strongly.</p><p>Just imagine a baseball glove. If it lies flat, the baseball will just roll over it. Now, imagine your hand is the molecular glue. Once your hand is inside, the glove forms a rounder structure that holds the baseball (the target) with a firm grip.</p><p>Of course, the real biology is more complicated than this simplified example. Small molecules do not always need a deep pocket to bind, and molecular glues can work in several different ways. But the basic idea is the same: a molecular glue acts as an adapter that allows two proteins to bind that otherwise would not interact, or would interact only weakly.</p><p>.</p><p><strong>Molecular Glues Occur Naturally</strong></p><p>Molecular glues do exist naturally. In fact, some have been used as drugs before scientists even understood how molecular glues work. One example is cyclosporin A, a naturally occurring molecule that is used to suppress the immune system, particularly to prevent rejection after organ transplantation.</p><p>Cyclosporin A first binds to cyclophilin A, a common and abundant protein inside cells. The newly formed complex can then bind to another protein and inhibit its function. I won’t get into more details here, but this example is particularly interesting because cyclophilin A is also the protein used by Rasonque.</p><p>.</p><p><strong>How does Rasonque work?</strong></p><p>Rasonque is not a naturally occurring molecule. It is a purpose-designed molecular glue that first binds to cyclophilin A, and the complex is then able to bind to RAS, which is a key player in many cancers. RAS helps regulate cell growth, cell division, and cell survival. In many cancers, RAS itself is mutated and stays activated. In others, changes elsewhere in the cell can cause normal, or wild-type, RAS to become overly active.</p><p>The Rasonque-cyclophilin A complex binds to active RAS and prevents it from sending its normal growth signals. Importantly, Rasonque can target many different forms of RAS, including both mutated and wild-type RAS. This approach showed significant improvements in patients with metastatic pancreatic cancer and led to the FDA approval of Rasonque in August 2026.</p><p>A <a href="https://www.nature.com/articles/d41586-026-02745-5">recent report</a> also highlighted early clinical results suggesting that switching off RAS using Rasonque might have potential against lung cancer.</p><p>.</p><p><strong>How does Iberdomide work?</strong></p><p>Connecting two proteins through a molecular glue can result in very different effects. Iberdomide, which recently received accelerated approval from the FDA to treat multiple myeloma in combination with other drugs, uses a different approach.</p><p>Iberdomide binds to cereblon, which is part of the cell’s protein-disposal system. The iberdomide-cereblon complex can then bind to IKZF1 and IKZF3, the proteins that multiple myeloma cells depend on to survive and grow. These proteins are marked for destruction and broken down by the cell, which helps counter the cancer.</p><p>Having a drug that brings a target protein to the cell’s protein-disposal machinery isn’t a new approach. PROteolysis TArgeting Chimeras (PROTACs) use a molecule with two arms, each designed to bind a different protein. One arm binds the target protein, while the other binds a protein that is part of the cell’s protein-disposal machinery. This brings the two together so the target can be marked for destruction.</p><p>A molecular glue works differently: the glue itself contributes to the binding interface between the two proteins and is required for them to form a stable interaction.</p><p>.</p><p><strong>In Summary</strong></p><p>Molecular glues are small molecules that bring together two proteins that would normally not interact, or would interact only weakly. This can make it possible to target proteins that were previously considered undruggable.</p><p>Depending on the design, bringing two proteins together can have very different outcomes. Rasonque, for example, uses this interaction to block active RAS. Iberdomide uses it to have selected proteins destroyed by the cell.</p><p>.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3eeb3b617ac6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What is so Special about Organoids?]]></title>
            <link>https://scienceworthknowing.medium.com/what-is-so-special-about-organoids-1315198f0b4a?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/1315198f0b4a</guid>
            <category><![CDATA[organoid]]></category>
            <category><![CDATA[regenerative-medicine]]></category>
            <category><![CDATA[drug-development]]></category>
            <category><![CDATA[stem-cells]]></category>
            <category><![CDATA[cancer-research]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Wed, 26 Aug 2026 17:38:16 GMT</pubDate>
            <atom:updated>2026-08-26T17:38:16.837Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*D_g857RB-_nZnzjfNt8lOQ.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>Scientists have been developing organoids for a long time, and their potential has been there from the beginning. Lately, there seems to be a clear shift from “potential” to actually using them. But what are organoids?</p><p>For this article, I have my disclaimer right at the beginning, as this is another very complicated topic that I intentionally simplify. This article’s focus is on understanding what organoids are and where we can apply them.</p><p>Let’s start with something easier, a single cell. Or actually, many copies of the same cell. Researchers have been using cells grown in a laboratory for many decades to study viruses, the impact of a drug, or how CRISPR can be used for genetic editing. Without using living cells, it is almost impossible to know what a drug will do and how it will impact the cell’s behavior and health. You might have read articles stating that AI can predict what happens inside a cell, which seems to counter what I just told you, but here’s the catch. AI is getting better at predicting what drugs (or viruses) do to cells, potentially reducing some experiments using living cells, but AI can only do so because it has learned from all the testing that has been done before in living cells.</p><p>If cells are taken directly from a patient and cultured in a laboratory, they are called primary cells. And cultured means that they are provided an environment in which the cells can live and divide. The problem is that primary cells usually have a limited lifespan or limited ability to divide in culture, if they can be cultured at all. Not all cells can be easily cultured in a laboratory.</p><p>Using cells that were derived from a cancer, or that are made cancerous (scientists can introduce genetic changes that promote continued cell division), overcomes this problem. Established cancer cell lines can theoretically divide indefinitely, so scientists can keep them in the laboratory for a long time. Usually, scientists culture the same type of cell in one petri dish, so all cells are derived from the same origin. This is called a cell line. One (in)famous cell line you might have already heard of is the HeLa cell line. These are cervical cancer cells that were taken from a young woman, Henrietta Lacks, and used without her consent. HeLa cells are still widely used in many laboratories worldwide. Rebecca Skloot’s book “The Immortal Life of Henrietta Lacks” covers the topic in depth.</p><p>In theory, each cell in a cell line is a clone of the others, but in reality, they are not 100% the same. They can accumulate differences, so they become more like brothers and sisters than identical twins. These cells usually grow next to each other on a surface, or they float around by themselves in a liquid. All of this has the advantage that adding a drug (or virus) to the cells allows most of the cells to be exposed to the drug (or virus), and because the cells are very similar, they often react in a similar way. This amplifies the overall signal, making it easier for scientists to identify what is happening. But the advantage is also the problem. Our organs are much more complicated. Cells can be very diverse; some cells are completely surrounded by other cells, so they can be shielded from drugs (or viruses). We also have an immune system that reacts to changes in individual cells. The human body is a lot more complex than what we can mimic in a cell line.</p><p>And this is where organoids come into play. Organoids are often made of different types of cells, forming a complex structure similar to parts of the organ in our body, yet all of that is grown in a laboratory, outside a human body. It seems obvious that organoids offer a much closer model to study drugs (or viruses) than cell lines do. But organoids are still not perfect; they do not fully reflect the organ in our body. In some cases, however, organoids get reasonably close, not only supporting drug and infectious disease research, but also opening the door for transplantation.</p><p>So, let’s take a closer look at what organoids actually are, and what the recent developments and progress are.</p><p>.</p><p><strong>What is an organoid?</strong></p><p>An organoid is a mix of different cell types that form a structure resembling an organ. It is grown in a laboratory, using cells that can organize themselves into this three-dimensional structure.</p><p>This sounds very abstract, so to make it more visual: Intestinal organoids form a hollow structure with an inner surface that resembles the lining of the gut. Kidney organoids form structures resembling parts of the kidney’s filtering units, and heart organoids can beat.</p><p>But organoids aren’t fully functional replicas of the organ, and they are also not the same size. Most organoids are a fraction of a millimeter to a few millimeters in size. There is no functional blood circulation and no complete immune system, yet an organoid is as close to the real thing as we can make it in the laboratory, and it can provide answers that cell lines simply can’t provide.</p><p>.</p><p><strong>How are organoids made in the laboratory?</strong></p><p>One way is using pluripotent stem cells. Pluripotent stem cells can develop into almost any kind of cell in the body. Similar cells are present at a very early stage of development. During development, these cells mature into specialized cell types. The irony for organoids is that scientists often start with mature cells and reprogram them back into a pluripotent stem-cell state, creating induced pluripotent stem cells (iPSCs). These iPSCs are then told to mature again into the organ-specific cells that create the organoid.</p><p>Before I describe how the organoid develops, I want to introduce a different type of cell that can be used. Instead of using pluripotent stem cells, scientists can also use adult tissue stem cells. Some of our organs constantly renew themselves, such as our skin, and the new skin cells come from tissue stem cells. Another example is bone marrow, which provides adult stem cells for our blood cells. These types of stem cells are already primed for one organ, but can still mature into different cell types within that tissue. For organs such as the brain, kidney and retina, organoids are typically grown from pluripotent stem cells instead, because suitable adult tissue stem cells are not readily available or do not generate the needed range of cells in culture.</p><p>The basic concept of the next steps is the same, regardless of whether pluripotent or adult tissue stem cells are used. The cells are often added to a gel, which holds the cells in place, but the gel is loose enough to allow cells to divide and position themselves among the other cells, while allowing nutrients and oxygen to reach them. To trigger development of the stem cells into organoids, researchers add a changing mixture of signaling molecules, mimicking some of the signals that guide development in the body. Research copies nature, and nature does as instructed: the cells divide, specialize and arrange themselves into a structure that resembles the organ, based on the information given by the signaling molecules.<br> As most organoids do not have a functional blood supply, oxygen and nutrients have to reach the cells passively (through diffusion), and that limits the size of the organoid.</p><p>On a side note, pluripotent and adult tissue stem cells can be derived from a patient, which makes the created organoid highly personalized.</p><p>.</p><p><strong>What are organoids used for?</strong></p><p>As I mentioned above, organoids are used in research because they provide a more complex model of biology compared to cell lines (which are also used, as they have other advantages such as being a lot easier to grow). As organoid models improve, they may also help reduce some animal testing by providing a more realistic human model in the laboratory.</p><p>I want to highlight a recent finding, which really shows what organoids can do. In a publication in <a href="https://www.nature.com/articles/s41586-026-10877-x"><em>Nature</em></a><em> </em>(August 2026), researchers reported that they kept human brain organoids growing for more than five years. This is particularly noteworthy as the cells followed the developmental stages seen in the brain over time. Their gene activity and epigenetic patterns (see my article about <a href="https://scienceworthknowing.medium.com/epigenetics-in-personalized-medicine-68c04a34cd6c"><strong>epigenetics</strong></a>) changed over time, and the organoids’ molecular age closely tracked how long they had been growing in the laboratory. Now, just to be clear, a five-year-old organoid is not the same as a five-year-old brain, but it still provides a model to study later stages of human brain development.</p><p>Another important application is cancer. Although cancer is not an organ, scientists can grow tumor organoids, which can mimic the tumor found in patients more closely than just growing tumor cells similar to the cell lines we discussed above. In other words, tumor organoids may one day support personalized cancer treatment, as they could allow screening for the best treatment before treating the patient. Research has shown that this is possible, but the approach is still far from routine clinical use.</p><p>And of course, tumor organoids allow scientists to study cancer. A recent publication in <a href="https://www.nature.com/articles/s41586-026-10806-y"><em>Nature</em></a> showed that many patient-derived cancer models, most of them organoids, stayed close to the actual cancer when grown in the laboratory for extended times, which could make them useful for studying drug responses (including drugs in development) and resistance.</p><p>Another promising area is transplants. Organoids can be used to grow regenerative tissue for transplantation. Don’t expect that organoids can replace an entire organ; they cannot. But cells or tissue grown as organoids may be used to repair a damaged part of an existing organ. We are still at the very early stage, but researchers have grown retinal organoids from stem cells, and then used sheets of tissue from them to treat retinitis pigmentosa (a disease in which the light-sensing cells of the retina gradually die) in two patients. Two years later, the transplanted tissue was still there, with no serious complications. The study was primarily about safety, not whether vision improved. That is a very promising start. If you are interested in the broader concept of cell therapy, please refer to my article “<a href="https://medium.com/@scienceworthknowing/what-is-cell-therapy-f10da6ebef2c"><strong>What Is Cell Therapy?</strong></a><strong>”</strong></p><p>.</p><p><strong>In Summary</strong></p><p>While organoids are simplified versions of our organs, they do offer features that a cell line does not and bring us a tiny step closer to modeling human development and disease more accurately. For now, organoids continue to play an important role in research, but recent work has provided an outlook on their potential.</p><p>.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1315198f0b4a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Using mRNA Vaccination to Fight Cancer]]></title>
            <link>https://scienceworthknowing.medium.com/using-mrna-vaccination-to-fight-cancer-6fdd72104ef3?source=rss-9dd71b53ebca------2</link>
            <guid isPermaLink="false">https://medium.com/p/6fdd72104ef3</guid>
            <category><![CDATA[science-communication]]></category>
            <category><![CDATA[oncology]]></category>
            <category><![CDATA[mrna-vaccine]]></category>
            <category><![CDATA[cancer-vaccine]]></category>
            <dc:creator><![CDATA[Peter Friebe]]></dc:creator>
            <pubDate>Wed, 19 Aug 2026 23:53:37 GMT</pubDate>
            <atom:updated>2026-08-19T23:53:37.208Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zyqL-y7A8dWKBRLLVfME9Q.png" /><figcaption>Image generated with the assistance of AI</figcaption></figure><p>Disclosure: I wrote this article and used AI as a “professional editor” to refine and shorten overly long or complicated sentences.</p><p>.</p><p>In my article “<a href="https://medium.com/@scienceworthknowing/lets-talk-about-vaccines-07252c21cece"><strong>Let’s Talk About Vaccines</strong></a><strong>” </strong>I covered the core concept of mRNA vaccines and also highlighted that this type of technology can be used to fight cancer. I recently wrote another article on mRNA vaccines, when the <a href="https://medium.com/@scienceworthknowing/an-mrna-flu-vaccine-is-on-the-horizon-c2c70d544553">first mRNA flu vaccine</a> was approved in the US. And now I have yet another article focusing on this technology, as we just got a glimpse of the potential benefits of mRNA vaccines to fight cancer.</p><p>There is a recent <a href="https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma">press release</a> (August 2026), stating that using personalized mRNA neoantigen vaccines in combination with Keytruda significantly improved outcomes, compared to just using Keytruda. It’s just a press release, with limited information, but an extremely promising outlook nevertheless. But then, what does this actually mean? What do the mRNA vaccines do, and how do they work?</p><p>Let’s take a closer look at how mRNA vaccines are used to fight cancer.</p><p>My usual disclaimer: this article is intentionally simplified. The real science and the regulatory details are complex, but you do not need all of them to follow the argument.</p><p>.</p><p><strong>How can we vaccinate against cancer?</strong></p><p>Hearing the word vaccination, I immediately think of preparing our body for an infection before it occurs, so that I won’t get sick, or at least not severely ill. It is something I do proactively, to protect myself.</p><p>But that’s not how it works to fight cancer. As I previously wrote: “Cancer vaccines are not designed to prevent the onset of disease, but to help the immune system recognize and attack existing tumors.”</p><p>To understand how cancer vaccines work, we first need to understand what cancer actually is. Cancer develops from our own cells. It develops from something that our immune system recognizes as self and usually does not attack, while bacteria and viruses can be detected as not self and attacked.</p><p>But for a cell to become cancerous, something must have changed (mutated) in the genome of that cell as the growth and division of healthy cells is tightly regulated. Changes in cancer cells can bypass these regulations and the cell gains the ability to grow and multiply in a less controlled way. And the changes inside a cancer cell make the cell a little bit more not self.</p><p>This is important, as cells constantly present small fragments of the proteins they make on their surface, using molecules called HLA (Human Leukocyte Antigen). The presented fragments are checked by patrolling immune cells, so called T cells, for self, or not self. The ones that are not self, because they contain a mutation, are called neoantigens.</p><p>This protection is crucial, as mutations in cells are actually not that uncommon. Most mutated cells never become cancerous, and one of our body’s protections is immune surveillance: T cells can recognize neoantigens and destroy the cells presenting them.</p><p>For cancer to develop, the cells must be able to overcome normal limits on growth and multiplication, and they must also avoid being eliminated by our immune system. And that last one is important: even though some cells have mutated, and our immune cells recognize these changes, cells can protect themselves from a T cell “attack” by using proteins called PD-L1 or PD-L2 (programmed death-ligand 1 and 2). These ligands bind to PD-1 (programmed cell death protein 1) on the immune cell and tell the cell to stop the attack.</p><p>And this is where a drug called Keytruda, or pembrolizumab, comes into play. This drug binds PD-1 — the receptor on the immune cell — so PD-L1 and PD-L2 can no longer stop the immune system from doing its job. In simple terms, Keytruda unleashes our immune system.</p><p>So, if our immune system can detect mutation, and Keytruda can unleash the immune response, what is the mRNA vaccination needed for?</p><p>Our immune system does fight cancer, and Keytruda is often used to boost the fight. But cancer is extremely complex. Cancerous cells within a tumor can have different mutations, not all neoantigens are equally presented via HLA, and even if they are presented, and Keytruda is given, our immune system may still not create the strong immune response needed to succeed.</p><p>This is where the mRNA vaccine helps. In the current study, the mRNA vaccine was personalized for each patient, designed to represent up to 34 neoantigens found in that person’s tumor. And providing those neoantigens using mRNA vaccine technology helps present them to immune cells and can strengthen the immune response against them. The mRNA vaccine helps to create a stronger immune response against the cancer.</p><p>.</p><p><strong>What did the results show so far?</strong></p><p>As stated above, only a press release summarized some of the findings from a clinical study, so we do not have all the details yet.</p><p>The study covered 1,137 patients with stage IIB to IV melanoma whose tumors had already been completely removed by surgery. The vaccine was given afterwards, to help the immune system destroy any cancer cells that weren’t removed through the surgery.</p><p>The study compared the outcome of patients who were only given Keytruda, or Keytruda and the mRNA vaccine. The press release only announced that the study was successful, and showed statistically significant improvements for the mRNA vaccinated group, but no details on how much better, or how long patients had been followed, were announced. <br> However, an earlier smaller study showed that after five years about 68.8% of the group that received the mRNA vaccine plus Keytruda were still cancer-free, compared with 49.1% on Keytruda alone.</p><p>.</p><p><strong>In Summary</strong></p><p>The numbers from the small study are extremely promising, 68.8% vs 49.1% cancer-free after 5 years. I am very much looking forward to the release of the larger study with the hope that the numbers are indeed confirmed. This is big.</p><p>And I also want to mention that the mRNA vaccine approach is tailored to target only the neoantigen presenting cancer cells, which is different from traditional chemotherapies, which attack tumor cells, but also certain healthy cells, which can result in severe side effects. On the other hand, Keytruda is not specific to cancer cells, so it can still cause side effects. <br> The press release did state that the combination’s safety looked consistent with earlier studies, with no new safety signals, but it shared no further detail.</p><p>This is also a highly personalized approach. Each vaccine is tailored specifically for the patient’s own tumor, a process that takes about six weeks, and even if approved, availability and coverage may limit accessibility. To be seen.</p><p>Nevertheless, based on the information that has been made publicly available, mRNA vaccines show promise for improving cancer treatment. And the mRNA vaccine approach is already being tested against other cancers, such as lung, bladder, kidney, and pancreatic cancer.</p><p>.</p><p><strong><em>If you’d like to keep reading:</em></strong></p><p>Subscribe to my newsletter on <a href="https://substack.com/@scienceworthknowing"><strong>Substack</strong></a> (free, email delivery)</p><p><strong><em>If you’d like to follow my work professionally (and read articles there as well):</em></strong></p><p>Connect with me on <a href="https://www.linkedin.com/in/friebepeter/"><strong>LinkedIn</strong></a></p><p><strong><em>If you find this writing useful and want to support independent science communication:</em></strong></p><p>You can support my work on <a href="https://patreon.com/ScienceWorthKnowing"><strong>Patreon</strong></a> (optional)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6fdd72104ef3" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>